| Status | Topic selection |
| Technology type | Medicine |
| Decision | Not selected |
| Reason for decision | Not eligible for Health Technology Evaluation guidance |
| Further information | Decision makers have concluded that the clear rationale to not evaluate your product is due to your product being a biosimilar of published TA509. Generic or biosimilar medicines are not considered by NICE if the branded version is recommended in NICE technology appraisal or highly specialised technologies guidance. Please see 3 Topics that are not usually considered by NICE | NICE-wide topic prioritisation: the manual | Guidance | NICE for further information. |
| ID number | 12094 |
Project Team
| Project lead | Danielle Lees |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 September 2024 | Topic selection |
| 10 September 2024 | Topic selection |
For further information on how we select topics for development, please see our page about topic selection